Fulgent Genetics Inc
$ 23.01
-0.73%
23 Feb - close price
- Market Cap 716,549,000 USD
- Current Price $ 23.01
- High / Low $ 23.22 / 22.68
- Stock P/E N/A
- Book Value 36.49
- EPS -1.40
- Next Earning Report 2026-02-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.04 %
- 52 Week High 31.04
- 52 Week Low 14.57
About
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Analyst Target Price
$33.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-01 | 2025-05-01 | 2025-02-26 | 2024-11-08 | 2024-08-02 | 2024-05-03 | 2024-02-28 | 2023-11-03 | 2023-08-04 | 2023-05-05 | 2023-02-28 |
| Reported EPS | 0.14 | -0.62 | 0.04 | 0.04 | 0.31 | 0.15 | -0.01 | 0.28 | -0.39 | -0.08 | -0.22 | -0.48 |
| Estimated EPS | -0.22 | -0.18 | -0.1794 | -0.369 | -0.15 | -0.3 | -0.32 | -0.29 | -0.33 | -0.33 | -0.43 | -0.56 |
| Surprise | 0.36 | -0.44 | 0.2194 | 0.409 | 0.46 | 0.45 | 0.31 | 0.57 | -0.06 | 0.25 | 0.21 | 0.08 |
| Surprise Percentage | 163.6364% | -244.4444% | 122.2965% | 110.8401% | 306.6667% | 150% | 96.875% | 196.5517% | -18.1818% | 75.7576% | 48.8372% | 14.2857% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FLGT
2026-02-20 07:57:44
Fulgent Genetics (FLGT) is projected to release its Q4 2025 earnings before the market opens on Friday, February 27th, with analysts forecasting earnings of $0.02 per share and $85.38 million in revenue. The company currently has a market capitalization of $719.28 million and a negative P/E ratio of -16.74, while Wall Street analysts hold a consensus "Hold" rating with an average $32.00 price target. Insider selling has been observed, and institutional investors collectively own 48.06% of the stock.
2026-02-13 23:27:00
Allianz Asset Management GmbH significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 119.6% in the third quarter of 2025, bringing its total holdings to 90,869 shares valued at approximately $2.05 million. This move is part of broader institutional investor activity, with several other hedge funds also modifying their positions in the company. Analyst sentiment for Fulgent Genetics is mixed, with an average "Hold" rating and a consensus price target of $32.00, while insider selling has also been noted recently.
2026-02-13 11:27:45
Fulgent Genetics, Inc. (NASDAQ: FLGT) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open. Management will host a conference call on the same day at 8:30 AM ET to discuss the results and answer questions, with a live audio webcast available on the company's investor relations website. Fulgent is a technology-based company with established laboratory services and a therapeutic development business focused on cancer drug candidates.
2026-02-12 12:58:15
Fulgent Genetics, Inc. announced it will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open. Following the release, management will host a conference call at 8:30 AM ET to discuss the results and answer questions. The call will be accessible via live audio webcast on the Investor Relations section of the company's website.
2026-02-12 12:58:03
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced it will release its fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026. The company will also host a conference call for investors on the same day at 8:30 AM ET to discuss the results and answer questions. Fulgent is a technology-based company with established laboratory services and therapeutic development businesses, aiming to transition into a fully integrated precision medicine company.
2026-02-12 12:00:00
Fulgent Genetics, Inc. (NASDAQ: FLGT) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before the market opens. Following the release, management will host a conference call at 8:30 AM ET to discuss the results and answer questions. The call will be accessible via a live audio webcast on the Investor Relations section of the company's website.
